Cargando…

Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances

Per- and polyfluoroalkyl substances (PFAS) are a broad class of synthetic chemicals; some are present in most humans in developed countries. Several studies have shown associations between certain PFAS, such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS), and reduced antib...

Descripción completa

Detalles Bibliográficos
Autores principales: Porter, Anna K., Kleinschmidt, Sarah E., Andres, Kara L., Reusch, Courtney N., Krisko, Ryan M., Taiwo, Oyebode A., Olsen, Geary W., Longnecker, Matthew P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489981/
https://www.ncbi.nlm.nih.gov/pubmed/36183490
http://dx.doi.org/10.1016/j.envint.2022.107537
_version_ 1784792989378281472
author Porter, Anna K.
Kleinschmidt, Sarah E.
Andres, Kara L.
Reusch, Courtney N.
Krisko, Ryan M.
Taiwo, Oyebode A.
Olsen, Geary W.
Longnecker, Matthew P.
author_facet Porter, Anna K.
Kleinschmidt, Sarah E.
Andres, Kara L.
Reusch, Courtney N.
Krisko, Ryan M.
Taiwo, Oyebode A.
Olsen, Geary W.
Longnecker, Matthew P.
author_sort Porter, Anna K.
collection PubMed
description Per- and polyfluoroalkyl substances (PFAS) are a broad class of synthetic chemicals; some are present in most humans in developed countries. Several studies have shown associations between certain PFAS, such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS), and reduced antibody concentration after vaccination against diseases such as Tetanus. Recent studies have reported associations between COVID-19 occurrence and exposure to certain types of PFAS. However, studies of antibody concentration after COVID-19 vaccination in relation to PFAS serum concentrations have not been reported. We examined COVID-19 antibody responses to vaccines and PFAS serum concentrations among employees and retirees from two 3M facilities, one of which historically manufactured PFOS, PFOA, and perfluorohexane sulfonic acid (PFHxS). Participants completed enrollment and follow-up study visits in the Spring of 2021, when vaccines were widely available. In total 415 participants with 757 observations were included in repeated measures analyses. Log-transformed concentrations of anti-spike IgG and neutralizing antibodies were modeled in relation to concentration of PFAS at enrollment after adjusting for antigenic stimulus group (9 groups determined by COVID-19 history and number and type of vaccination) and other variables. The fully adjusted IgG concentration was 3.45 percent lower (95% CI −7.03, 0.26) per 14.5 ng/mL (interquartile range) increase in PFOS; results for neutralizing antibody and PFOS were similar. For PFOA, PFHxS, and perfluorononanoic acid (PFNA), the results were comparable to those for PFOS, though of smaller magnitude. In our study data, the fully adjusted coefficients relating concentration of vaccine-induced antibodies to COVID-19 and interquartile range difference in serum concentration of PFOS, PFOA, PFHxS, and PFNA were inverse but small with confidence intervals that included zero. Our analysis showed that the coefficient for the four PFAS examined in detail was considerably affected by adjustment for antigenic stimulus group.
format Online
Article
Text
id pubmed-9489981
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-94899812022-09-21 Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances Porter, Anna K. Kleinschmidt, Sarah E. Andres, Kara L. Reusch, Courtney N. Krisko, Ryan M. Taiwo, Oyebode A. Olsen, Geary W. Longnecker, Matthew P. Environ Int Full Length Article Per- and polyfluoroalkyl substances (PFAS) are a broad class of synthetic chemicals; some are present in most humans in developed countries. Several studies have shown associations between certain PFAS, such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS), and reduced antibody concentration after vaccination against diseases such as Tetanus. Recent studies have reported associations between COVID-19 occurrence and exposure to certain types of PFAS. However, studies of antibody concentration after COVID-19 vaccination in relation to PFAS serum concentrations have not been reported. We examined COVID-19 antibody responses to vaccines and PFAS serum concentrations among employees and retirees from two 3M facilities, one of which historically manufactured PFOS, PFOA, and perfluorohexane sulfonic acid (PFHxS). Participants completed enrollment and follow-up study visits in the Spring of 2021, when vaccines were widely available. In total 415 participants with 757 observations were included in repeated measures analyses. Log-transformed concentrations of anti-spike IgG and neutralizing antibodies were modeled in relation to concentration of PFAS at enrollment after adjusting for antigenic stimulus group (9 groups determined by COVID-19 history and number and type of vaccination) and other variables. The fully adjusted IgG concentration was 3.45 percent lower (95% CI −7.03, 0.26) per 14.5 ng/mL (interquartile range) increase in PFOS; results for neutralizing antibody and PFOS were similar. For PFOA, PFHxS, and perfluorononanoic acid (PFNA), the results were comparable to those for PFOS, though of smaller magnitude. In our study data, the fully adjusted coefficients relating concentration of vaccine-induced antibodies to COVID-19 and interquartile range difference in serum concentration of PFOS, PFOA, PFHxS, and PFNA were inverse but small with confidence intervals that included zero. Our analysis showed that the coefficient for the four PFAS examined in detail was considerably affected by adjustment for antigenic stimulus group. The Authors. Published by Elsevier Ltd. 2022-11 2022-09-21 /pmc/articles/PMC9489981/ /pubmed/36183490 http://dx.doi.org/10.1016/j.envint.2022.107537 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Full Length Article
Porter, Anna K.
Kleinschmidt, Sarah E.
Andres, Kara L.
Reusch, Courtney N.
Krisko, Ryan M.
Taiwo, Oyebode A.
Olsen, Geary W.
Longnecker, Matthew P.
Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances
title Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances
title_full Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances
title_fullStr Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances
title_full_unstemmed Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances
title_short Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances
title_sort antibody response to covid-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489981/
https://www.ncbi.nlm.nih.gov/pubmed/36183490
http://dx.doi.org/10.1016/j.envint.2022.107537
work_keys_str_mv AT porterannak antibodyresponsetocovid19vaccinesamongworkerswithawiderangeofexposuretoperandpolyfluoroalkylsubstances
AT kleinschmidtsarahe antibodyresponsetocovid19vaccinesamongworkerswithawiderangeofexposuretoperandpolyfluoroalkylsubstances
AT andreskaral antibodyresponsetocovid19vaccinesamongworkerswithawiderangeofexposuretoperandpolyfluoroalkylsubstances
AT reuschcourtneyn antibodyresponsetocovid19vaccinesamongworkerswithawiderangeofexposuretoperandpolyfluoroalkylsubstances
AT kriskoryanm antibodyresponsetocovid19vaccinesamongworkerswithawiderangeofexposuretoperandpolyfluoroalkylsubstances
AT taiwooyebodea antibodyresponsetocovid19vaccinesamongworkerswithawiderangeofexposuretoperandpolyfluoroalkylsubstances
AT olsengearyw antibodyresponsetocovid19vaccinesamongworkerswithawiderangeofexposuretoperandpolyfluoroalkylsubstances
AT longneckermatthewp antibodyresponsetocovid19vaccinesamongworkerswithawiderangeofexposuretoperandpolyfluoroalkylsubstances